Final answer:
False. H19 lncRNA typically has a role in epigenetic regulation, including IGF2, and gene expression changes are pivotal in cancer development. However, it's not correct that H19 lncRNA silences the enhancer regulating IGF2 in Wilms' tumor specifically.
Step-by-step explanation:
False. The H19 lncRNA (long non-coding RNA) does not act to silence the enhancer that regulates IGF2 expression specifically in Wilms' tumor. However, it's important to note that H19 lncRNA has a role in gene expression control and can be involved in the epigenetic regulation of certain genes, including IGF2 in some contexts. Normally, H19 acts to maintain the silenced state of the maternal IGF2 allele through its action at the imprinting control region, but the situation can vary in different types of cancers like Wilms' tumor, where this regulatory mechanism can be disrupted.
In general, alterations in gene expression play a significant role in cancer development. As stated, changes in epigenetic regulation, transcription, and other cellular processes can contribute to malignancy. For example, mutations in genes such as tumor suppressor genes or oncogenes, which either suppress or promote cell division respectively, can both lead to cancer. This showcase how crucial the proper management of gene expression is for maintaining normal cellular function and preventing cancer.